Literature DB >> 11861873

Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs.

Ronald P van Rij1, Janny A Visser, Rieneke M E van Praag, Ronald Rientsma, Jan M Prins, Joep M A Lange, Hanneke Schuitemaker.   

Abstract

A viral reservoir of human immunodeficiency virus type 1 (HIV-1)-infected, resting CD4(+) T cells persists despite suppression of plasma viremia by combination antiretroviral therapy. In a longitudinal analysis of three patients treated with a five-drug regimen, both R5 and X4 HIV-1 variants persisted in the cellular reservoir for up to 3 years.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11861873      PMCID： PMC136002          DOI： 10.1128/jvi.76.6.3054-3058.2002

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  26 in total

1.  In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline.

Authors:  H Blaak; A B van't Wout; M Brouwer; B Hooibrink; E Hovenkamp; H Schuitemaker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.

Authors:  J M Prins; S Jurriaans; R M van Praag; H Blaak; R van Rij; P T Schellekens; I J ten Berge; S L Yong; C H Fox; M T Roos; F de Wolf; J Goudsmit; H Schuitemaker; J M Lange
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

3.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection.

Authors:  H Kuster; M Opravil; P Ott; E Schlaepfer; M Fischer; H F Günthard; R Lüthy; R Weber; R W Cone
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

5.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Authors:  G Dornadula; H Zhang; B VanUitert; J Stern; L Livornese; M J Ingerman; J Witek; R J Kedanis; J Natkin; J DeSimone; R J Pomerantz
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

6.  Factors influencing T-cell turnover in HIV-1-seropositive patients.

Authors:  J M McCune; M B Hanley; D Cesar; R Halvorsen; R Hoh; D Schmidt; E Wieder; S Deeks; S Siler; R Neese; M Hellerstein
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

7.  Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production.

Authors:  H Blaak; L J Ran; R Rientsma; H Schuitemaker
Journal:  Virology       Date:  2000-02-15       Impact factor: 3.616

8.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Authors:  L Zhang; B Ramratnam; K Tenner-Racz; Y He; M Vesanen; S Lewin; A Talal; P Racz; A S Perelson; B T Korber; M Markowitz; D D Ho
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

9.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

10.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Authors:  M E Sharkey; I Teo; T Greenough; N Sharova; K Luzuriaga; J L Sullivan; R P Bucy; L G Kostrikis; A Haase; C Veryard; R E Davaro; S H Cheeseman; J S Daly; C Bova; R T Ellison; B Mady; K K Lai; G Moyle; M Nelson; B Gazzard; S Shaunak; M Stevenson
Journal:  Nat Med       Date:  2000-01       Impact factor: 87.241
View more
  4 in total

1.  Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.

Authors:  Ruy M Ribeiro; Mette D Hazenberg; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa.

Authors:  Nontokozo D Matume; Denis M Tebit; Laurie R Gray; Marie-Louise Hammarskjold; David Rekosh; Pascal O Bessong
Journal:  J Clin Virol       Date:  2018-02-15       Impact factor: 3.168

3.  High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment.

Authors:  Elizabeth R Johnston; Lynn S Zijenah; Solomon Mutetwa; Rami Kantor; Chonticha Kittinunvorakoon; David A Katzenstein
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  Alterations in HIV-1 gp120 V3 region are necessary but not sufficient for coreceptor switching in CRF07_BC in China.

Authors:  Lei Zhang; Liying Ma; Zheng Wang; Yan Wang; Jing Zhang; Haining Wang; Yiming Shao
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.